Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Original Paper

Effect of Cardioactive Drugs on Action Potential Generation and Propagation in Embryonic Stem Cell-Derived Cardiomyocytes

Reppel M.1,2 · Igelmund P.1 · Egert U.3 · Juchelka F.1 · Hescheler J.1 · Drobinskaya I.1

Author affiliations

1Institute for Neurophysiology, University of Cologne2Medical Clinic II, University of Lübeck3Bernstein Center for Computational Neuroscience, Albert-Ludwigs-Universität of Freiburg*The authors contributed equally to the manuscript

Corresponding Author

Irina Drobinskaya, Jürgen Hescheler

Institute for Neurophysiology, University of Cologne

Robert-Kochstr. 39, D-50931-Cologne (Germany)

Tel. +49 221/478-86772, Fax: +49 221/478-3834

E-Mail irina.drobinskaya@uni-koeln.de or j.hescheler@uni-koeln.de

Related Articles for ""

Cell Physiol Biochem 2007;19:213–224

Do you have an account?

Login Information





Contact Information










I have read the Karger Terms and Conditions and agree.



Abstract

Extracellular recordings of spontaneous electrical activity in contracting cardiac clusters differentiated from murine embryonic stem cells enable to study electrophysiological features of this in-vitro cardiac-like tissue as well as effects of pharmacological compounds on its chronotropy and electrical conduction. To test if the microelectrode array (MEA) system could serve as a basis for development of a pharmacological screening tool for cardioactive drugs, we used spontaneously beating outgrowths of three-dimensional ES cell aggregates (“embryoid bodies”, EBs) plated onto substrate-integrated MEAs. The effects of the L-type Ca2+ channel antagonist verapamil and Na+ and K+ channel blockers (tetrodotoxin, 4-aminopyridine, and sparfloxacin) on the deduced interrelated cardiac network function were investigated. Application of 10-6 M verapamil led to arrhythmic spiking with a burst-like pattern; at a higher concentration (10-5 M) the drug caused a sustained negative chronotropy up to complete stop of beating. In the presence of tetrodotoxin a conduction block was observed. Since modulation of K+ channel activity can cause anti- or proarrhythmic effects, the influence of K+ channel blockers, namely 4-aminopyridine and sparfloxacin, was investigated. 4-aminopyridine (2x10-3 M) significantly stabilized beating frequency, while the field potential duration (FPD) was concentration-dependently prolonged up to 2.7-fold. Sparfloxacin (3x10-6 M) stabilized the beating frequency as well. At a higher concentration of sparfloxacin (3x10-5 M), a significant prolongation of the spike duration was registered; application of the drug caused also early afterdepolarizations. The results demonstrate a suitability of the studied in-vitro cardiac cell model for pharmacological drug testing in cardiovascular research.

© 2007 S. Karger AG, Basel


Article / Publication Details

First-Page Preview
Abstract of Original Paper

Accepted: December 21, 2006
Published online: May 02, 2007
Issue release date: March 2007

Number of Print Pages: 12
Number of Figures: 0
Number of Tables: 0

ISSN: 1015-8987 (Print)
eISSN: 1421-9778 (Online)

For additional information: http://www.karger.com/CPB


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.